title: Safety and efficacy of primary thromboprophylaxis in cancer patients.
abstract: Cancer is often complicated by venous thromboembolism (VTE), a common and potentially fatal complication associated with poor prognosis in these patients. An increased incidence of VTE is being observed due to the advanced age of cancer patients, the thrombogenic effect of novel drugs and advances in the diagnosis of related complications. In this review, we look at five different risk groups of cancer patients with an increased probability of developing VTE, including hospitalized patients undergoing chemotherapy, patients undergoing a surgical procedure, ambulatory patients undergoing chemotherapy, patients with a central venous access and patients receiving antiangiogenic drugs or anticoagulant therapy due to previous chronic diseases. The aim of this review is to summarize the most important clinical evidence reported to date on the suitability of primary thromboprophylaxis to cancer patients. Recommendations have drawn up for each group based on current evidence and guidelines to facilitate decision-making in clinical practice.
authors.affiliation: Servicio de Oncología Médica, Hospital San Pedro de Alcántara, Avda. Pablo Naranjo, s/n., 10003, Cáceres, Spain. naxto@hotmail.com.
authors.forename: I
authors.initials: I
authors.lastname: García Escobar
authors.affiliation: ICO-Hospital Duran i Reynalds, L'Hospitalet de Llobregat, Barcelona, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Antonio Rebollo
authors.affiliation: Hospital Universitario de Móstoles, Móstoles, Madrid, Spain.
authors.forename: S
authors.initials: S
authors.lastname: García Adrián
authors.affiliation: Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Rodríguez-Garzotto
authors.affiliation: Hospital General Universitario Gregorio Marañón, Madrid, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Muñoz Martín
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D011379:Prognosis; D054556:Venous Thromboembolism / Q000209:etiology* / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants
keywords: Antiangiogenic drugs; Central venous catheter; Oncological patients; Primary prophylaxis; Thrombosis; Venous thromboembolism